Facial Function in Bell Palsy in a Cohort of Children Randomized to Prednisolone or Placebo 12 Months After Diagnosis

Franz E. Babl, David Herd, Meredith L. Borland, Amit Kochar, Ben Lawton, Jason Hort, Adam West, Shane George, Ed Oakley, Catherine L. Wilson, Sandy M. Hopper, John A. Cheek, Stephen Hearps, Mark T. Mackay, Stuart R. Dalziel, Katherine J. Lee

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Background: Information on the medium-term recovery of children with Bell palsy or acute idiopathic lower motor neuron facial paralysis is limited. Methods: We followed up children aged 6 months to <18 years with Bell palsy for 12 months after completion of a randomized trial on the use of prednisolone. We assessed facial function using the clinician-administered House-Brackmann scale and the modified parent-administered House-Brackmann scale. Results: One hundred eighty-seven children were randomized to prednisolone (n = 93) or placebo (n = 94). At six months, the proportion of patients who had recovered facial function based on the clinician-administered House-Brackmann scale was 98% (n = 78 of 80) in the prednisolone group and 93% (n = 76 of 82) in the placebo group. The proportion of patients who had recovered facial function based on the modified parent-administered House-Brackmann scale was 94% (n = 75 of 80) vs 89% (n = 72 of 81) at six months (OR 1.88; 95% CI 0.60, 5.86) and 96% (n = 75 of 78) vs 92% (n = 73 of 79) at 12 months (OR 3.12; 95% CI 0.61, 15.98). Conclusions: Although the vast majority had complete recovery of facial function at six months, there were some children without full recovery of facial function at 12 months, regardless of prednisolone use.

Original languageEnglish
Pages (from-to)44-47
Number of pages4
JournalPediatric Neurology
Volume153
Early online date6 Feb 2024
DOIs
Publication statusPublished - Apr 2024

Fingerprint

Dive into the research topics of 'Facial Function in Bell Palsy in a Cohort of Children Randomized to Prednisolone or Placebo 12 Months After Diagnosis'. Together they form a unique fingerprint.

Cite this